These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
311 related articles for article (PubMed ID: 25336340)
1. Human mesenchymal stromal cells attenuate graft-versus-host disease and maintain graft-versus-leukemia activity following experimental allogeneic bone marrow transplantation. Auletta JJ; Eid SK; Wuttisarnwattana P; Silva I; Metheny L; Keller MD; Guardia-Wolff R; Liu C; Wang F; Bowen T; Lee Z; Solchaga LA; Ganguly S; Tyler M; Wilson DL; Cooke KR Stem Cells; 2015 Feb; 33(2):601-14. PubMed ID: 25336340 [TBL] [Abstract][Full Text] [Related]
2. Differential Effect of MyD88 Signal in Donor T Cells on Graft-versus-Leukemia Effect and Graft-versus-Host Disease after Experimental Allogeneic Stem Cell Transplantation. Lim JY; Ryu DB; Lee SE; Park G; Choi EY; Min CK Mol Cells; 2015 Nov; 38(11):966-74. PubMed ID: 26552489 [TBL] [Abstract][Full Text] [Related]
3. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation. Teshima T; Hill GR; Pan L; Brinson YS; van den Brink MR; Cooke KR; Ferrara JL J Clin Invest; 1999 Aug; 104(3):317-25. PubMed ID: 10430613 [TBL] [Abstract][Full Text] [Related]
4. Human multipotent adult progenitor cells effectively reduce graft-vs-host disease while preserving graft-vs-leukemia activity. Metheny L; Eid S; Wuttisarnwattana P; Auletta JJ; Liu C; Van Dervort A; Paez C; Lee Z; Wilson D; Lazarus HM; Deans R; Vant Hof W; Ktena Y; Cooke KR Stem Cells; 2021 Nov; 39(11):1506-1519. PubMed ID: 34255899 [TBL] [Abstract][Full Text] [Related]
5. Transplantation of Graft Anti-Host Cytotoxic T Lymphocytes Along with Allogeneic Bone Marrow Skips Macrophage-Induced Graft-Versus-Host Disease. Yoshida R; Yamana H; Hayashi M; Yasuda E; Shibayama Y; Hirose Y; Tanigawa N; Uchiyama K; Kubota T J Interferon Cytokine Res; 2021 Sep; 41(9):310-318. PubMed ID: 34543129 [TBL] [Abstract][Full Text] [Related]
6. Enrichment of IL-12-producing plasmacytoid dendritic cells in donor bone marrow grafts enhances graft-versus-leukemia activity in allogeneic hematopoietic stem cell transplantation. Darlak KA; Wang Y; Li JM; Harris WA; Owens LM; Waller EK Biol Blood Marrow Transplant; 2013 Sep; 19(9):1331-9. PubMed ID: 23810844 [TBL] [Abstract][Full Text] [Related]
7. Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect. Schmaltz C; Alpdogan O; Horndasch KJ; Muriglan SJ; Kappel BJ; Teshima T; Ferrara JL; Burakoff SJ; van den Brink MR Blood; 2001 May; 97(9):2886-95. PubMed ID: 11313285 [TBL] [Abstract][Full Text] [Related]
8. CCL1 blockade alleviates human mesenchymal stem cell (hMSC)-induced pulmonary fibrosis in a murine sclerodermatous graft-versus-host disease (Scl-GVHD) model. Lim JY; Ryu DB; Kim TW; Lee SE; Park G; Yoon HK; Min CK Stem Cell Res Ther; 2020 Jun; 11(1):254. PubMed ID: 32586381 [TBL] [Abstract][Full Text] [Related]
10. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects. Giver CR; Montes RO; Mittelstaedt S; Li JM; Jaye DL; Lonial S; Boyer MW; Waller EK Biol Blood Marrow Transplant; 2003 Oct; 9(10):616-32. PubMed ID: 14569558 [TBL] [Abstract][Full Text] [Related]
11. Repifermin (keratinocyte growth factor-2) reduces the severity of graft-versus-host disease while preserving a graft-versus-leukemia effect. Clouthier SG; Cooke KR; Teshima T; Lowler KP; Liu C; Connolly K; Ferrara JL Biol Blood Marrow Transplant; 2003 Sep; 9(9):592-603. PubMed ID: 14506661 [TBL] [Abstract][Full Text] [Related]
12. MicroRNA-17-92 controls T-cell responses in graft-versus-host disease and leukemia relapse in mice. Wu Y; Heinrichs J; Bastian D; Fu J; Nguyen H; Schutt S; Liu Y; Jin J; Liu C; Li QJ; Xia C; Yu XZ Blood; 2015 Sep; 126(11):1314-23. PubMed ID: 26138686 [TBL] [Abstract][Full Text] [Related]
13. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras. Xia G; Truitt RL; Johnson BD Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723 [TBL] [Abstract][Full Text] [Related]
15. [Effect of bone marrow mesenchymal stem cells on acute graft versus host disease and graft versus leukemia after allogeneic bone marrow transplantation]. Hu WB; Gao QP; Chen YH Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Jun; 13(3):404-7. PubMed ID: 15972130 [TBL] [Abstract][Full Text] [Related]
17. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma. Fowler DH; Gress RE Leuk Lymphoma; 2000 Jul; 38(3-4):221-34. PubMed ID: 10830730 [TBL] [Abstract][Full Text] [Related]
18. Optimization of adipose tissue-derived mesenchymal stem cells by rapamycin in a murine model of acute graft-versus-host disease. Kim KW; Moon SJ; Park MJ; Kim BM; Kim EK; Lee SH; Lee EJ; Chung BH; Yang CW; Cho ML Stem Cell Res Ther; 2015 Oct; 6():202. PubMed ID: 26497134 [TBL] [Abstract][Full Text] [Related]
19. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2. Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666 [TBL] [Abstract][Full Text] [Related]
20. Flt-3L Expansion of Recipient CD8α Markey KA; Kuns RD; Browne DJ; Gartlan KH; Robb RJ; Martins JP; Henden AS; Minnie SA; Cheong M; Koyama M; Smyth MJ; Steptoe RJ; Belz GT; Brocker T; Degli-Esposti MA; Lane SW; Hill GR Clin Cancer Res; 2018 Apr; 24(7):1604-1616. PubMed ID: 29367429 [No Abstract] [Full Text] [Related] [Next] [New Search]